Researcher profile

Ali Ajdari

Ali Ajdari contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
1topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2026arXiv

Bi-level Multi-criteria Optimization for Risk-informed Radiotherapy

In radiation therapy (RT) treatment planning, multi-criteria optimization (MCO) supports efficient plan selection but is usually solved for population-based dosimetric criteria and ignores patient-specific biological risk, potentially compromising outcomes in high-risk patients. We propose risk-guided MCO, a one-shot method that embeds a clinical risk model into conventional MCO, enabling interactive navigation between dosimetric and biological endpoints. The proposed algorithm uses a special order relation to fuse the classical MCO sandwiching algorithm with bi-level optimization, restricting the Pareto set to plans that achieve improvement in the secondary risk objective for user-defined, acceptable loss in primary clinical objectives. Thus, risk-guided MCO generates risk-optimized counterparts of clinical plans in a single run rather than by sequential or lexicographic planning. To assess the performance, we retrospectively analyzed 19 lung cancer patients treated with RT. The endpoint was the risk of grade 2+ radiation pneumonitis (RP), modeled using bootstrapped stepwise logistics regression with interaction terms, including baseline lung function, smoking history, and dosimetric factors. The risk-guided plans yielded a mean reduction of 8.0% in total lung V20 and 9.5% in right lung V5, translating into an average RP risk reduction of 7.7% (range=0.3%-20.1%), with small changes in target coverage (mean -1.2 D98[%] for CTV) and modest increase in heart dose (mean +1.74 Gy). This study presents the first proof-of-concept for integrating biological risk models directly within multi-criteria RT planning, enabling an interactive balance between established population-wide dose protocols and individualized outcome prediction. Our results demonstrate that the risk-informed MCO can reduce the risk of RP while maintaining target coverage.

preprint2021arXiv

Adjustable robust treatment-length optimization in radiation therapy

Traditionally, optimization of radiation therapy (RT) treatment plans has been done before the initiation of RT course, using population-wide estimates for patients' response to therapy. However, recent technological advancements have enabled monitoring individual patient response during the RT course, in the form of biomarkers. Although biomarker data remains subject to substantial uncertainties, information extracted from this data may allow the RT plan to be adapted in a biologically informative way. We present a mathematical framework that optimally adapts the treatment-length of an RT plan based on the acquired mid-treatment biomarker information, while accounting for the inexact nature of this information. We formulate the adaptive treatment-length optimization problem as a 2-stage problem, wherein the information about the model parameters gathered during the first stage influences the decisions in the second stage. Using Adjustable Robust Optimization (ARO) techniques we derive explicit optimal decision rules for the stage-2 decisions and solve the optimization problem. The problem allows for multiple worst-case optimal solutions. To discriminate between these, we introduce the concept of Pareto Adjustable Robustly Optimal (PARO) solutions. In numerical experiments using lung cancer patient data, the ARO method is benchmarked against several other static and adaptive methods. In case of exact biomarker information, there is sufficient space to adapt, and numerical results show that taking into account both robustness and adaptability is not necessary. In case of inexact biomarker information, accounting for adaptability and inexactness of biomarker information is particularly beneficial when robustness (w.r.t. organ-at-risk (OAR) constraint violations) is of high importance. If minor OAR violations are allowed, a nominal folding horizon approach is a good performing alternative.